ABVC BioPharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ABVC Nasdaq 2836 www.abvcpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ABVC BioPharma, Inc.

ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders - Jun 23rd, 2026 6:30 am
ABVC BioPharma Reports 2025 Form 10-K - Mar 3rd, 2026 3:00 pm
ABVC BioPharma Provides Corporate and Structural Update - Feb 24th, 2026 6:30 am
ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States - Dec 2nd, 2025 6:30 am
ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030 - Nov 26th, 2025 6:30 am
ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received - Nov 21st, 2025 6:30 am
ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million - Nov 18th, 2025 6:30 am
ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025 - Nov 3rd, 2025 6:00 am
ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950 - Oct 31st, 2025 5:00 am
ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology - Oct 17th, 2025 5:30 am
ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production - Oct 8th, 2025 5:30 am
ABVC BioPharma, Inc. (ABVC) Reports 103% Asset Surge, Eyeing Phase III Trials for Depression Therapies - Sep 23rd, 2025 5:11 pm